GLC-001: Glaucoma
A small-molecule program aimed at restoring aqueous outflow through the trabecular meshwork to lower intraocular pressure in glaucoma.
Program Overview
Scientific Rationale
The pressure problem
Glaucoma is a leading cause of irreversible blindness. In its most common forms, fluid drains too slowly through the eye’s trabecular meshwork, raising intraocular pressure and progressively damaging the optic nerve. Lowering that pressure is the only intervention proven to slow the disease.
Targeting outflow directly
Rather than reducing fluid production, this program addresses the source of resistance in the trabecular-meshwork outflow pathway, with the goal of durable pressure reduction.
Our Approach
AI-guided discovery
Omic’s platform explored candidate chemistries against the outflow mechanism and used digital patient models to prioritize molecules with the best predicted efficacy and tolerability profile.
Where it stands
The program is in lead optimization. The specific molecular target remains undisclosed.
Program details, including specific molecular targets, are disclosed selectively under confidentiality as part of partnership and licensing discussions.
Interested in Licensing GLC-001?
Contact us to discuss licensing opportunities and partnership terms